Evidence map›Paper›PMID 35804523›Full record

ArticleAnimals : an open access journal from MDPI2022

A Scenario Analysis for Implementing Immunocastration as a Single Solution for Piglet Castration.

Li Lin-Schilstra, Paul T M Ingenbleek

Abstract read
In one paragraph

Article in Animals : an open access journal from MDPI, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Li Lin-SchilstraCollege of Economics and Management, Nanjing Agricultural University, Nanjing 210095, China.ORCID 0000-0002-7584-9186
Paul T M IngenbleekMarketing and Consumer Behaviour Group, Wageningen University & Research, 6706 KN Wageningen, The Netherlands.ORCID 0000-0001-8793-716X

Funding

Dutch Research Council grantnr 696231
6 · The paper itself

Abstract

Painful castration of male piglets to avoid boar taint can potentially be replaced by three more ethical alternatives: entire male production in combination with a detection method, immunocastration (an active vaccination against the gonadotrophin-releasing factor, GnRF), and castration with pain relief (anesthesia and/or analgesia). With the aim of abandoning piglet castration and facilitating internal trade, the European Union (EU) was initially in favor of a single alternative. Immunocastration was proposed as a potential solution, but it has not yet been sufficiently assessed regarding its market potential. To address this point, this paper uses scenario analysis to examine whether and under what conditions immunocastration could be the general solution sought by the EU. The study constructs two extreme scenarios: one in which all uncertain elements negatively influence the growth of immunocastration; another in which all uncertain elements have positive influences. These scenarios provide insights into the variance in possible futures for the implementation of immunocastration. The results show that it is unlikely that immunocastration will become a single solution for all producers in the EU, because it is not the optimal solution for all types of EU pork production systems (i.e., cost-efficiency oriented, quality oriented, animal-friendly oriented, import dependent). Rather than debating and looking for evidence about which single method is the best for the entire EU, EU authorities are advised to allow the co-existence of all alternatives and to develop protocols for applying them in the pork industry.

Indexed as

animal welfareboar taintEuropean marketgonadotrophin-releasing factorpig meat

Identifiers

PMID35804523
PMCPMC9264866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.